Bristol-Myers Squibb

Performance indicators

2023: On the list of companies with the largest R&D costs

The chart shows 12 months of data as of April 2023.
For Amazon shows the costs of technology and content (not R&D).
ByteDance statistics date back to 2021 (according to the Wall Street Journal)

2021: 6th in the world in terms of prescription drug sales: $45.7 billion

Data for 2021

2020

Share in the global pharmaceutical market - 4.7%

Bristol Myers' share in the global pharmaceutical market was 4.7%. Read more here.

Global Cancer Drugs Market Share - 18%

Bristol Myers' share of the global cancer drug market was 18% (Evaluate data). Read more here.

History

2023: Bristol Myers Squibb buys Mirati Therapeutics for $5.8 billion

On October 8, 2023, the American pharmaceutical company Bristol Myers Squibb announced an agreement to purchase Mirati Therapeutics, a company specializing in the development of drugs for the treatment of malignancies. The total value of the transaction reaches $5.8 billion, and it is planned to complete it in the first half of 2024. Read more here.

2022

Bristol Myers Squibb acquires cancer developer for $4.1 billion

On June 3, 2022, it became known that Bristol Myers Squibb (BMS) is acquiring cancer drug developer Turning Point Therapeutics in a deal worth $4.1 billion. Read more here.

Sale of Russian business

On May 19, 2022, Bristol Myers Squibb announced its withdrawal from the Russian market. The company transfers the corresponding business to Svix Helskea LLC , a Russian subsidiary of Swiss Swixx BioPharma (engaged in the sale and distribution of medicines and medical devices of international companies in Central and Eastern Europe). Financial and other parameters of the transaction are not disclosed.

It is noted that the process of transferring Russian assets to Bristol Myers Squibb began on May 18 and will last several weeks - until June. Most of the company's employees in Russia were invited to move to Swix Helskea. They will also be compensated.

Pharmgiant Bristol Myers Squibb transfers Russian business to local partner

We believe that this solution will help ensure constant access to our medicines for Russian patients, - explained in Bristol Myers Squibb.

Bristol Myers Squibb specializes in the development and production of drugs for the treatment of cancer, endocrine and infectious diseases, for example, the antitumor "Opdivo" and "Yervoy." The company provided patients with the opportunity to access modern therapy for free as part of clinical trials, but after the sale of Russian business, these experiments in the country will be discontinued. All studies will be discontinued in May 2022.

The company was conducting a clinical trial of the drug for Crohn's disease, which was supposed to be completed in 2024. Previously, the pharmaceutical giant conducted a study of drugs for plaque psoriasis and systemic lupus erythematosus.

Bristol Myers Squibb became the first major pharmaceutical company to finally leave the Russian market due to a special operation by the Russian Federation and Ukraine. Prior to that, Pfizer, Sanofi, Reckitt Benckiser, Johnson & Johnson, GSK and Takeda only suspended part of their activities in the country. So, they abandoned the planned clinical studies.^[1]

2021: Fine for concealing side effects of Plavix

In mid-February 2021, the court forced Bristol-Myers Squibb and Sanofi to pay the state of Hawaii more than $834 million for concealing the side effects of the anti-platelet drug Plavix, which is used to prevent repeated myocardial infarction or stroke. Read more here.

2020: Purchase of pharmaceutical company MyoKardia

On October 5, 2020, Bristol-Myers biopharmaceutical company from the United States announced the purchase of MyoKardia. The deal is valued at about $13 billion and will allow Bristol-Myers to expand its heart drug business. Read more here.

2017: Caforio moves to head board

In early May 2017, Bristol-Myers Squibb chief executive Giovanni Kaforio replaced Lamberto Andreotti as chairman of the board of Bristol-Myers Squibb.

Notes